Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Introducing ‘BYOP’ clinical trials

The company Curebase is promoting the concept of 'bring-your-own-physician' clinical trials.

By Brian Buntz | August 3, 2021

Doctor patient clinical trials

Image courtesy of Pixabay.

BYOD — “bring your own device” — became a common term in tech circles a decade ago. Now with primary care doctors playing a growing role in clinical trials, the provider of decentralized clinical research software Curebase (San Francisco) aims to popularize the concept of “BYOP” — “bring your own physician.” That is, the company is working to connect patients with local physicians to collect real-world data and execute trials.

In any event, decentralized and hybrid clinical trials continue to gain ground as the pandemic persists. The trend is elevating the role of community-based clinical trials in areas such as oncology.

Additionally, physicians are playing a growing role in spurring clinical trial recruitment, according to a recent survey from Informa Pharma Intelligence and Rare Patient Voice. Almost half (48%) of patients taking part in a clinical trial had first learned of the opportunity from their physician. Among those who had not participated in a clinical trial, 81% said they would be more likely to participate if their physicians informed them of a possibility of enrolling.

Tom Lemberg

Tom Lemberg

“We have multiple clinical trials right now where patients can participate with their own doctor,” said Tom Lemberg, CEO of Curebase.

One of those trials enables expectant mothers across the country to join a clinical trial. Whereas similar studies in the past would have required patients to visit a local academic medical center to participate, the trial enables women to go to their local doctor. “They can go to their own OB-GYN physician for their normal second- and third-trimester visits, and we can collect data at the point of care,” Lemberg said.

Decentralized studies don’t necessarily mean “clinical trials from your couch,” Lemberg said. Enabling doctors outside of academic medical centers to play an integral role in clinical trials is “the next big step to realize the full potential,” he added.

The clinical trials market was worth $44.3 billion in 2020, according to Grand View Research. Decentralized clinical trials make up a growing slice of the market, thanks in large part to the pandemic. “COVID really forced pharmaceutical companies and regulators to invest in this method,” Lemberg said.

One of CureBase’s customers, InBios International Inc., won emergency use authorization for its SCoV-2 Ag Detect rapid SARS-CoV-2 test. The clinical data InBios filed with FDA was based on a decentralized clinical trial. That study drew data from COVID-19 drive-through testing and clinic-based sites.

“We turned ordinary healthcare providers into researchers,” Lemberg said. “These were not traditional research sites. They were just COVID testing clinics that we activated to form our research network.”

Although fully decentralized clinical trials are not always feasible, they offer several advantages. In addition to reducing COVID-19 transmission risks, they can also help “achieve greater diversity, access to more patients in different demographic groups, socioeconomic groups, racial groups, etc.,” Lemberg said.


Filed Under: clinical trials, Drug Discovery
Tagged With: clinical trials, covid-19, Curebase, decentralized clinical trial, physicians
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50